Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Swedish Orphan Biovitrum AB (Publ)
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB (Publ)
Update Il y a 4 ans
An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed with hereditary tyrosinemia type 1
To evaluate the steady-state exposure to nitisinone during once and twice daily dosing of Orfadin
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB (Publ)
Update Il y a 4 ans
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely
The primary objective of this study is to demonstrate that rhBSSL improves growth in preterm infants as compared with placebo when administered in infant formula or PBM.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB (Publ)
Update Il y a 4 ans
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablative chemo-radiotherapy conditioning regimen with allogeneic hematopoietic stem cell transplant (HSCT)
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablati...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Swedish Orphan Biovitrum AB (Publ)
Update Il y a 4 ans
A study to evaluate the effects of palifermin in reducing mouth ulceration in subjects with locally advanced head and neck cancer
To evaluate the pharmacokinetic profile and biological activity on buccal mucosae of palifermin administered at the dose of 120 μg/kg IV in a cohort of at least 16 (3 palifermin : 1 placebo) locally a...
Country
None
organs
None
Specialty
None
Closed trial
More information